Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
Avid Bioservices (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization, has announced it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close. The company will also host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) on the same day. During the webcast, Avid's senior management will discuss the financial results and review recent corporate developments. Investors and interested parties can access the live or archived webcast through the company's investor relations website.
Avid Bioservices (NASDAQ:CDMO), un'organizzazione dedicata allo sviluppo e alla produzione di prodotti biologici su contratto, ha annunciato che riporterà i risultati finanziari per il primo trimestre dell'anno fiscale 2025 il 9 settembre 2024, dopo la chiusura del mercato. L'azienda ospiterà anche un webcast alle 13:30 ora del Pacifico (16:30 ora dell'Est) lo stesso giorno. Durante il webcast, il management senior di Avid discuterà i risultati finanziari e esaminerà i recenti sviluppi aziendali. Gli investitori e le parti interessate possono accedere al webcast in diretta o registrato attraverso il sito web delle relazioni con gli investitori dell'azienda.
Avid Bioservices (NASDAQ:CDMO), una organización dedicada al desarrollo y fabricación de productos biológicos por contrato, ha anunciado que informará los resultados financieros del primer trimestre del año fiscal 2025 el 9 de septiembre de 2024, después del cierre del mercado. La compañía también llevará a cabo un webcast a la 1:30 PM Hora del Pacífico (4:30 PM Hora del Este) el mismo día. Durante el webcast, la alta dirección de Avid discutirá los resultados financieros y revisará los recientes desarrollos corporativos. Los inversores y partes interesadas pueden acceder al webcast en vivo o grabado a través del sitio web de relaciones con inversores de la compañía.
Avid Bioservices (NASDAQ:CDMO)는 계약 생물학 제품 개발 및 제조에 전념하는 조직으로, 2024년 9월 9일에 2025 회계연도 1분기 재무 결과를 시장 종료 후 발표할 것이라고 발표했습니다. 회사는 같은 날 태평양 표준시 오후 1시 30분 (동부 표준시 오후 4시 30분)에 웹캐스트를 개최할 예정입니다. 웹캐스트 동안 Avid의 고위 경영진이 재무 결과를 논의하고 최근 기업 발전을 검토할 것입니다. 투자자 및 관심 있는 당사자는 회사의 투자자 관계 웹사이트를 통해 실시간 또는 보관된 웹캐스트에 액세스할 수 있습니다.
Avid Bioservices (NASDAQ:CDMO), une organisation dédiée au développement et à la fabrication de produits biologiques sous contrat, a annoncé qu'elle publiera ses résultats financiers pour le premier trimestre de l'exercice fiscal 2025 le 9 septembre 2024, après la clôture du marché. L'entreprise organisera également un webinaire à 13h30, heure du Pacifique (16h30, heure de l'Est) le même jour. Lors du webinaire, la haute direction d'Avid discutera des résultats financiers et passera en revue les développements récents de l'entreprise. Les investisseurs et les parties intéressées peuvent accéder au webinaire en direct ou archivé via le site des relations avec les investisseurs de l'entreprise.
Avid Bioservices (NASDAQ:CDMO), ein auf die Entwicklung und Herstellung biologischer Produkte spezialisierte Vertragsorganisation, hat bekannt gegeben, dass sie am 9. September 2024 nach Börsenschluss die finanziellen Ergebnisse für das erste Quartal des Geschäftsjahres 2025 bekannt geben wird. Das Unternehmen wird an diesem Tag auch um 13:30 Uhr Pazifischer Zeit (16:30 Uhr Eastern Time) eine Webkonferenz abhalten. Während der Webkonferenz wird das Top-Management von Avid die finanziellen Ergebnisse besprechen und die aktuellen Unternehmensentwicklungen überprüfen. Investoren und Interessierte können über die Investor-Relations-Website des Unternehmens auf die Live- oder Archiv-Webkonferenz zugreifen.
- None.
- None.
TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.
About Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO) is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With more than 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
FAQ
When will Avid Bioservices (CDMO) report its Q1 FY2025 financial results?
What time is Avid Bioservices' (CDMO) Q1 FY2025 earnings webcast scheduled for?
Where can I access Avid Bioservices' (CDMO) Q1 FY2025 earnings webcast?
What will be discussed during Avid Bioservices' (CDMO) Q1 FY2025 earnings call?
